Associated Papers
Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives.
Pitton Rissardo J et al.
Brain Sciences, 2025
The crucial role of VPS35 and SHH in Parkinson's disease: Understanding the mechanisms behind the neurodegenerative disorder.
Bhardwaj K et al.
Brain Research, 2024
Targeting Protein Misfolding and Aggregation as a Therapeutic Perspective in Neurodegenerative Disorders.
Sidoryk-Węgrzynowicz M et al.
International Journal of Molecular Sciences, 2024
Genetic-based diagnostics of Parkinson's disease and other Parkinsonian syndromes.
Somerville EN et al.
Expert Review of Molecular Diagnostics, 2024
Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies.
Dai L et al.
Cellular and Molecular Life Sciences : Cmls, 2024
Mutant mice with rod-specific VPS35 deletion exhibit retinal α-synuclein pathology-associated degeneration.
Fu C et al.
Nature Communications, 2024
VPS35 and retromer dysfunction in Parkinson's disease.
Rowlands J et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 2024
Retromer stabilization using a pharmacological chaperone protects in an α-synuclein based mouse model of Parkinson's.
Eleuteri S et al.
Research Square, 2023
Chaperone-mediated autophagy in neurodegenerative diseases: mechanisms and therapy.
Liu Y et al.
Molecular and Cellular Biochemistry, 2023
VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease.
Chen X et al.
Molecular Neurodegeneration, 2023
Genetic Evidence for Endolysosomal Dysfunction in Parkinson's Disease: A Critical Overview.
Yahya V et al.
International Journal of Molecular Sciences, 2023
Sphingolipids in neurodegenerative diseases.
Pan X et al.
Frontiers in Neuroscience, 2023
Autophagy and Its Association with Genetic Mutations in Parkinson Disease.
Erekat NS
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2022
Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.
Williams ET et al.
Neurobiology of Disease, 2022
Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM et al.
Journal of Parkinson's Disease, 2021
Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models.
Abe T et al.
Frontiers in Neurology, 2021
The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction.
Bellomo G et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2020
Mitochondrial Homeostasis and Signaling in Parkinson's Disease.
Scorziello A et al.
Frontiers in Aging Neuroscience, 2020
Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson's disease.
Ammal Kaidery N et al.
Molecular and Cellular Neurosciences, 2019
Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration.
Chen X et al.
Proceedings of the National Academy of Sciences of the United States of America, 2019
Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives.
Park JS et al.
Current Neurology and Neuroscience Reports, 2018
Autonomic dysfunction in genetic forms of synucleinopathies.
Chelban V et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2018
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.
Zeng XS et al.
Frontiers in Aging Neuroscience, 2018
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Schneider SA et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2017
Epidemiology, environmental risk factors and genetics of Parkinson's disease.
Delamarre A et al.
Presse Medicale (paris, France : 1983), 2017
VPS35, the Retromer Complex and Parkinson's Disease.
Williams ET et al.
Journal of Parkinson's Disease, 2017
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease.
Michel PP et al.
Neuron, 2016
Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2016
VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease.
Miura E et al.
Neurobiology of Disease, 2014
Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Tsika E et al.
Human Molecular Genetics, 2014
Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy.
Zavodszky E et al.
Nature Communications, 2014
Genetic variants and animal models in SNCA and Parkinson disease.
Deng H et al.
Ageing Research Reviews, 2014
The VPS35 gene and Parkinson's disease.
Deng H et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2013
Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
Wales P et al.
Journal of Parkinson's Disease, 2013
[Alzheimer disease. Epidemiology, genetics and physiopathological hypotheses].
Blain H et al.
Presse Medicale (paris, France : 1983), 1998
[From Parkinson's disease to Lewy body disease].
Bordet R et al.
Presse Medicale (paris, France : 1983), 1992